The safety of nivolumab for the treatment of advanced non-small cell lung cancer

Expert Opinion on Drug Safety

Volumn 16, Issue 1, 2017, Pages 101-109

  Metro, Giulio ^a   Ricciuti, Biagio ^a   Brambilla, Marta ^a   Baglivo, Sara ^a   Soli, Irene ^a   Minenza, Elisa ^b   Leonardi, Giulia Costanza ^a   D’arpino, Alessandro ^a   Colabrese, Daniela ^a   Tazza, Marco ^a   Zicari, Daniela ^a   Minotti, Vincenzo ^a   Chiari, Rita ^a  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b S MARIA HOSPITAL   (Italy)

Author keywords

Immune checkpoint blockade; immune related adverse events; nivolumab; non small cell lung cancer; safety

Indexed keywords

CREATININE; DOCETAXEL; IMMUNOGLOBULIN G4; NIVOLUMAB; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLITIS; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; ENCEPHALITIS; FATIGUE; HUMAN; HYPERSENSITIVITY; HYPOTHYROIDISM; LUNG DISEASE; NAUSEA; NEPHRITIS; NEUROMUSCULAR JUNCTION DISORDER; NON SMALL CELL LUNG CANCER; OPPORTUNISTIC INFECTION; PHARMACODYNAMICS; PHARMACOKINETICS; PNEUMONIA; PRURITUS; RASH; RHEUMATIC POLYMYALGIA; SKIN TOXICITY; THYROIDITIS; UNSPECIFIED SIDE EFFECT; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; COMPARATIVE STUDY; IMMUNOLOGY; LUNG NEOPLASMS; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85003976949     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2017.1267725     Document Type: Article

References (32)

1. Siegel RL, Miller KD, Jemal A., Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367–1380.
3. Howlander N, Noone AM, Krapcho M, et al. eds. SEER cancer statistics review. Bethesda (MD):National Cancer Institute; 1975-2013.
4. Califano R, Abidin A, Tariq NU, et al. Beyond EGFR and ALK inhibition:unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer. Cancer Treat Rev. 2015;41:401–411.
5. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264.
6. OPDIVO–Products–Bristol-Myers Squibb. [cited 2016 Sep1]. Available from:http://packageinserts.bms.com/pi/pi_opdivo.pdf
7. Opdivo EMA SmPC. [cited 2016 Sep1]. Available from:http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003985/human_med_001876.jsp&mid=WC0b01ac058001d124
8. Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063):a phase 2, single-arm trial. Lancet Oncol. 2015;16:257–265.• Pivotal phase II study showing the activity and good tolerability of nivolumab 3 mg/kg every 2 weeks in pretreated advanced squamous NSCLC.
9. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–135.•• Pivotal phase III trial showing superiority of nivolumab 3 mg/kg every 2 weeks compared with standard docetaxel chemotherapy in platinum-pretreated advanced squamous NSCLC.
10. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–1639.•• Pivotal phase III trial showing superiority of nivolumab 3 mg/kg every 2 weeks compared with standard docetaxel chemotherapy in platinum-pretreated advanced non-squamous NSCLC.
11. Swaika A, Hammond WA, Joseph RW. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol. 2015;67:4–17.
12. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors:safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–3175.
13. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.• Phase I study showing the efficacy of different schedules of nivolumab across multiple advanced cancers, including NSCLC.
14. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (Anti-Programmed death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33:2004–2012.
15. Borghaei H, Brahmer J, Hoern L, et al. Nivolumab vs. docetaxel in patients with advanced NSCLC:checkMate 017/057 2-year update and exploratory cytokine profile analysis. J Clin Oncol. 2016;34(suppl):abstr 9025.
16. Crinò L, Bidoli P, Delmonte A, et al. Italian cohort of nivolumab Expanded Access Programme (EAP):preliminary data from a real-world population. J Clin Oncol. 2016;34(suppl):abstr3067.
17. Hussein M, McCleod M, Chandler J, et al. Safety and efficacy of nivolumab in an ongoing trial of PD-L1+/- patient population with metastatic non-small cell lung cancer. J Thorac Oncol. 2015;10(suppl2):abstr S175.
18. Singh H, Kim G, Maher VE, et al. FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers. J Clin Oncol. 2016;34(suppl):abstr10010.
19. Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2016 Sep 29;pii:mdw443.
20. Eigentler TK, Hassel JC, Berking C, et al. Diagnosis, monitoring and management of immune-related adverse drug reaction of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7–18.
21. Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2016 Sep 19.
22. Nishino M, Chambers ES, Chong CR, et al. Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer. Cancer Immunol Res. 2016;4:289–293.
23. Hughes J, Vudattu N, Sznol M, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015;38:e55–e57.
24. Law-Ping-Man S, Martin A, Briens E, et al. Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer. Rheumatology (Oxford). 2016;55:2087–2089.
25. Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2016 Jun 15;pii:annrheumdis-2016-209595.
26. Kimura T, Fukushima S, Miyashita A, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 2016;107:1055–1058.
27. Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities:a collaborative position paper. Ann Oncol. 2016;27:559–574.
28. Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34:2980–2987.
29. Rizvi NA, Hellmann MD, Brahmer JR, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34:2969–2979.
30. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.
31. Hellmann MD, Gettinger SN, Goldman JW, et al. CheckMate 012:safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. J Clin Oncol. 2016;34(suppl):abstr 3001.
32. Socinski M, Creelan B, Horn L, et al. CheckMate 026:a phase 3 trial of nivolumab vs investigator’s choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC. Ann Oncol. 2016;27(suppl 6):vi552–vi587, abstract LBA7_PR.